GlassScriptPhysician profile
Nakema Rollins
NPI 1427771930
$7,125.99
in general payments reported to CMS, 2019-2025
29 companies · $2,855 in 2025
The $2,855 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $371 · 2023: $2,307 · 2024: $1,592 · 2025: $2,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,655 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,654.98 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,143.57 | 2023-2025 | Jakafi, Niktimvo, Zynyz |
| Sanofi-Aventis U.S. LLC | $688.97 | 2023-2025 | |
| Stemline Therapeutics INC. | $606.00 | 2023-2025 | Orserdu |
| Janssen Biotech, INC. | $446.96 | 2023-2024 | Tecvayli, Rybrevant, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $428.35 | 2023-2025 | Reblozyl, Breyanzi |
| Daiichi Sankyo INC. | $378.98 | 2024-2025 | Vanflyta, Datroway |
| Jazz Pharmaceuticals INC. | $357.49 | 2025 | |
| Pfizer INC. | $339.63 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $309.57 | 2023-2024 | Tagrisso, Calquence, Imfinzi |
| Kite Pharma, INC. | $222.85 | 2023 | Yescarta |
| Astellas Pharma US INC | $211.01 | 2024 | Xospata |
| Regeneron Healthcare Solutions, INC. | $207.36 | 2023-2024 | Libtayo |
| Aadi Bioscience, INC. | $160.00 | 2022 | |
| Novocure INC. | $144.74 | 2025 | Optune Lua (Novottf-200t) |
| Abbvie INC. | $123.81 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $120.18 | 2022 | |
| Blueprint Medicines Corporation | $118.26 | 2023 | Ayvakit |
| Glaxosmithkline, LLC. | $115.29 | 2024 | Jemperli |
| Genzyme Corporation | $114.16 | 2023 | |
| Gilead Sciences, INC. | $113.83 | 2024 | Trodelvy |
| Sobi, INC | $102.54 | 2025 | |
| Servier Pharmaceuticals LLC | $101.72 | 2023 | |
| Syndax Pharmaceuticals, INC. | $94.45 | 2025 | Revuforj |
| Caris Mpi, INC. | $91.21 | 2025 | Mi Cancer Seek |
| Bayer Healthcare Pharmaceuticals INC. | $86.95 | 2023 | |
| Gt Medical Technologies, INC | $83.73 | 2023 | Gammatile |
| Janssen Scientific Affairs, LLC | $76.80 | 2023 | |
| Geron Corporation | $76.80 | 2025 | Rytelo |
| Adaptive Biotechnologies Corporation | $60.78 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nakema Rollins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.